OCD Affects Three-Quarters of a Million UK Residents but Treatment Trials Fall Short

Inadequate clinical trials are hampering the development of effective obsessive-compulsive disorder treatments, according to new BMJ editorial analysis.

Obsessive-compulsive disorder affects around 750,000 people across the UK at any given time. But inadequate clinical trials are preventing the translation of research into effective treatments for one of psychiatry’s most disabling conditions.

The British Medical Journal has published an editorial warning that poor trial design is holding back progress for patients living with OCD. The condition affects about 1.2% of the population each year, with lifetime prevalence reaching 2.3%.

View tweet from @bmj_latest

The Scale of the Problem

Women bear a disproportionate burden of OCD, with past-year prevalence of 1.8% compared to just 0.5% in men. The condition typically emerges early in life, with the most common age of onset between 18 and 29 years.

Nearly a quarter of males show symptoms before age 10. For females, the disorder usually emerges during adolescence, with peripartum and postpartum phases representing periods of increased risk.

Around half of all OCD cases are classified as severe, even as less than 25% are considered mild. Yet the condition frequently remains underdiagnosed and undertreated, with only a small fraction of patients receiving appropriate medical care.

Treatment Challenges

Current evidence-based treatments fail to help 40-60% of people with OCD. The editorial authors argue that inadequate trial methodology is preventing improvements in clinical practice.

OCD ranks as the fourth most common mental disorder globally. But it receives limited research funding compared to conditions like psychosis and dementia, constraining treatment development.

The condition is often misunderstood in public discourse. Casual references to “OCD quirks” conflate normal behaviours with the clinical disorder, potentially contributing to diagnostic delays.

The Research Gap

Experts emphasise the need for stronger clinical trials to develop better treatments for OCD patients who don’t respond to current therapies.

Patient advocacy groups emphasise the need for better awareness and reduced stigma alongside improved access to evidence-based treatments. The healthcare system perspective highlights how limited research funding constrains service planning and treatment options.

Source: @bmj_latest

Key Takeaways

OCD affects 750,000 people in the UK, with women 1.6 times more likely to be affected than men

Around 50% of cases are severe, but current treatments fail to help 40-60% of patients

Inadequate clinical trial design is preventing the development of more effective treatments

What This Means for Kent Residents

Kent residents experiencing OCD symptoms can access support through NHS Kent and Medway ICB mental health services, including local GP practices and community mental health teams that provide assessment and treatment. Improved clinical trial evidence could enhance treatment options available through Kent’s NHS services in the future. Anyone concerned about OCD symptoms should contact their GP or NHS 111 for guidance, as the Samaritans (116 123) provide 24/7 support for mental health concerns.

Source: @bmj_latest

Published: 23 March 2026

Source: @bmj_latest on X. This article has been researched and rewritten with editorial balance by Kent Local News.